biote Corp (BTMD) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
biote Corp stock (BTMD) is currently trading at $1.47. biote Corp PE ratio is 2.07. biote Corp PS ratio (Price-to-Sales) is 0.35. Analyst consensus price target for BTMD is $3.17. WallStSmart rates BTMD as Sell.
- BTMD PE ratio analysis and historical PE chart
- BTMD PS ratio (Price-to-Sales) history and trend
- BTMD intrinsic value — DCF, Graham Number, EPV models
- BTMD stock price prediction 2025 2026 2027 2028 2029 2030
- BTMD fair value vs current price
- BTMD insider transactions and insider buying
- Is BTMD undervalued or overvalued?
- biote Corp financial analysis — revenue, earnings, cash flow
- BTMD Piotroski F-Score and Altman Z-Score
- BTMD analyst price target and Smart Rating
biote Corp
📊 No data available
Try selecting a different time range
BTMD Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · biote Corp (BTMD)
BTMD trades at a significant discount to its Graham intrinsic value of $5.03, offering a 58% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
biote Corp (BTMD) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, institutional own.. Concerns around market cap and operating margin. Mixed signals suggest waiting for clearer direction before acting.
biote Corp (BTMD) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
63.58% held by institutions, strong professional interest
Supporting Valuation Data
biote Corp (BTMD) Areas to Watch (6)
Revenue declining -6.90%, a shrinking business
Earnings declining -36.70%, profits shrinking
Very thin margins with limited operational efficiency
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Decent profitability, keeps $14 per $100 revenue
biote Corp (BTMD) Detailed Analysis Report
Overall Assessment
This company scores 36/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 2.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Institutional Own.. Valuation metrics including Price/Sales (0.35) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Revenue Growth, EPS Growth, Operating Margin. Some valuation metrics including Price/Book (2.96) suggest expensive pricing. Growth concerns include Revenue Growth at -6.90%, EPS Growth at -36.70%, which may limit upside. Profitability pressure is visible in Operating Margin at 9.40%, Profit Margin at 14.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at 9.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -6.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Revenue Growth and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BTMD Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BTMD's Price-to-Sales ratio of 0.35x trades at a deep discount to its historical average of 1.1x (6th percentile). The current valuation is 86% below its historical high of 2.58x set in May 2021, and 6% above its historical low of 0.33x in Jan 2026. Over the past 12 months, the PS ratio has compressed from ~0.5x as trailing revenue scaled faster than the stock price.
Compare BTMD with Competitors
Top MEDICAL CARE FACILITIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for biote Corp (BTMD) · HEALTHCARE › MEDICAL CARE FACILITIES
The Big Picture
biote Corp faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 192M with 7% decline year-over-year. Profit margins of 14.1% are healthy, with room for further expansion as the business scales.
Key Findings
Generating 6M in free cash flow and 8M in operating cash flow. Earnings are translating into actual cash generation.
Debt-to-equity ratio of -1.46 indicates a conservative balance sheet with 28M in cash.
Revenue contracted 7% YoY. Worth determining whether this is cyclical or structural.
What to Watch Next
Margin expansion: can biote Corp push profit margins above 15% as the business scales?
Debt management: total debt of 106M is significantly higher than cash (28M). Monitor refinancing risk.
Sector dynamics: monitor MEDICAL CARE FACILITIES industry trends, competitive moves, and regulatory changes that could impact biote Corp.
Bottom Line
biote Corp faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About biote Corp(BTMD)
NASDAQ
HEALTHCARE
MEDICAL CARE FACILITIES
USA
biote corp. The company is headquartered in Irvine, Texas.